scores were lower than the norm post-op for all breast cancer patients.
PURPOSE:
Despite associations with greater quality of life, autologous transfer represents a declining proportion of US breast reconstructions. Poor physician reimbursement relative to prosthetic reconstructions may be a barrier contributing to this trend. The study aims to evaluate the impact of relative physician payments for common methods of immediate breast reconstruction (IBR).
METHODS:
Following IRB approval, the Blue Health Intelligence (BlueCross/BlueShield) national claims database was analyzed from 2009 through 2013. Procedural volume and payments for plastic surgeon professional services were calculated for two common IBR methods: tissue expander (TE) and free flap (FF).
RESULTS:
Of 25,209 patients who had IBR, 84.4% received tissue expanders (TE) and 15.6% underwent free flaps(FF). Five-year growth-rate in TE: FF was 4.3%. Average physician payment increased 18% for TE versus 14% for FF. Payment variation, expressed as the standard deviation relative to mean, was significantly greater for FF (116%) than TE(59%). Markets that experienced a $1,000 gain in TE payment, increased the TE:FF on average 103% (p<.05). The same gains in FF payment increased the FF:TE by 74% (p<.05).
CONCLUSION:
Physician payments are increasing at a greater rate for TE than FF. Markets are significantly more responsive to payment changes in TE than FF, suggesting larger scale changes in payment would be needed to influence flap growth. An alternative interpretation is that barriers beyond reimbursement may influence the number of FF performed. Larger payment variation for FF supports greater room for reimbursement negotiation.
Foot Rejuvenation with Pedal Fat Grafting: A Randomized Cross-Over Clinical Trial
Stephanie E. Dreifuss, MD, Danielle Minteer, PhD, Jeffrey Gusenoff, MD University of Pittsburgh Medical Center, Pittsburgh, PA PURPOSE: Pedal fat pad atrophy is a devastating condition affecting 30% of patients over the age of 60 and impacting foot function, pain, and appearance. We have previously reported in a one-year randomized clinical trial that fat grafting to the foot results in statistically significant improvements in pain and quality of life outcomes, despite fat loss over time. We hypothesize that pedal fat grafting may benefit dermal and soft tissue thickness, which may account for the prolonged symptomatic improvement despite loss of the grafted fat.
METHODS:
Patients with fat pad atrophy of the forefoot were enrolled into a randomized cross-over clinical trial. Group 1 underwent fat grafting immediately upon enrollment with 2-year follow-up. Group 2 was managed conservatively for 1 year upon enrollment then crossed over into the fat grafting group with 1-year follow-up. Fat was harvested utilizing the Coleman method and an average of 4-6 ccs of fat were injected into the ball of each affected foot. Patients followed up at 1, 2, 6 and 12 months postoperatively, at which times pedal ultrasounds were performed to determine thickness of the fat pad and the dermis overlying each metatarsal head. Over the course of the study period, the Manchester Foot Pain and Disability Index, a validated survey assessing functional limitation, pain intensity, and personal appearance, was administered to study participants.
